After administration of 20 mg ACIPHEX delayed-release tablets once daily for eight days, the mean percent of time that gastric pH greater than 3 or gastric pH greater than 4 after a single dose Day 1 ...

The FDA has approved Aciphex (rabeprazole sodium, from Eisai) for the short-term treatment of gastroesophageal reflux disease (GERD) in adolescents ≥12 years of age. In a 12-week study, Aciphex was ...

This leaflet answers some common questions about RABEPRAZOLE MYLAN. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved Aciphex for treatment of gastroesophageal reflux disease in adolescents age 12 and older, Tokyo-based Eisai’s North America ...

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said. Eisai ...

Co announces that the FDA has granted final approval for the Company's Abbreviated New Drug Application for Rabeprazole Sodium Delayed-Release Tablets, 20 mg. TEVA's Rabeprazole Sodium Delayed-Release ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using RABEPRAZOLE VIATRIS? RABEPRAZOLE VIATRIS contains ...

Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of the ...

In February, the indications for Aciphex were expanded to include the treatment of patients with symptomatic gastroesophageal reflux disease GERD. Aciphex, a proton pump inhibitor, can now be used for ...